Lung Cancer Clinical Trial
Official title:
Effect of Low Molecular Weight Heparin on Survival of Stage I,II or IIIA Non Small Cell Lung Cancer. A Multicenter, Open, Randomized Controlled Trial.
Experiments suggest that low molecular weight heparin (LMWH) inhibits tumor growth and metastasis. Studies in humans suggest that LMWH is associated with a higher survival in patients with cancer related thrombosis. Two recent studies suggest that LMWH may increase the survival of patients with cancer who do not have an associated thrombosis. The purpose of the study is to assess the effect of LMWH on the overall survival of patients with localized non-small cell lung cancer after complete surgical resection.
Phase III, prospective, multicentric, randomized, controlled, open trial in parallel groups
with a blind adjudication of all end-point criteria.
Reference therapy :
Patients randomized to the control group will receive postoperative treatment according to
local practice in the participating centers. However, the participating centers will have to
comply with the following guidelines.
Adjuvant chemotherapy:
Adjuvant chemotherapy will be offered in all patients with stage II and stage IIIA cancers.
Adjuvant chemotherapy will be platin based and include two drugs for a maximum of 4 cycles.
Each center will have to select one regimen before the beginning of the study for all
patients included in the study.
Preoperative chemotherapy:
Patients who had chemotherapy before surgery can be included in the study provided that they
had a complete surgical resection. In this case the tumor stage for stratification will be
the pathologic stage assessed after surgery.
Stage I cancers:
Patients with stage I cancer who will not be selected for postoperative chemotherapy can be
included in the study. Contraindication to chemotherapy Patients with a contraindication to
postoperative chemotherapy and those who refuse chemotherapy can be included in the study
provided they fulfill all inclusion and exclusion criteria.
Experimental treatment:
Experimental treatment is tinzaparin administered subcutaneously once a day at the dose of
100 IU/Kg during a twelve week period beginning after a maximum period of 8 weeks after
surgery. Patients randomized in the experimental group will receive adjuvant postoperative
treatment according to local practice with the same guidelines as in the control group.
- Patient follow-up:
All patients will be followed according to local practice, but at least two outpatient
visits with a chest radiograph will be planned each year during the three year follow-up
period after last inclusion.
- Duration of the trial:
Inclusion period (first patient in to last patient in) : 6 years. Patient total follow-up
(from surgery to end of follow-up) : 3 years after last inclusion (first enrolled patients
were followed 9 years). Total study period : 9 years.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|